The Changing Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-based Discussion Webinar (2020)

AUA
America/New York GMT -4 summer

Description

The Changing Landscape of Advanced Prostate Cancer Treatment:

A Guidelines and Case-based Discussion Webinar

Wednesday, October 21, 2020

 

Agenda

9:00 – 9:05 a.m. Welcome

Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

9:05 – 9:15 a.m. Pre-Test

Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

Session 1

9:15 – 9:35 a.m. Identification of High Risk Disease and Initial Management of Biochemical Recurrence

Dr. Boorjian

9:35 – 9:50 a.m. Imaging of Advanced Prostate Cancer

Dr. Stratton

9:50 – 10:10 a.m. Management of mHSPC: A Case-based Discussion of Chemohormonal Therapy and the Evolving Role of Local Therapy in Oligometastatic Disease

Moderators: David F. Jarrard, MD & Dr. Lang

10:10 – 10:30 a.m. M0 CRPC: Treatment Options and Goals of Therapy

Dr. Cookson

10:30 a.m. – 10:45 Break

10:45 – 11:10 a.m. Genetic Testing in Advanced Prostate Cancer

Dr. Gomella

11:10 – 11:35 a.m. Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents in mHSPC and CRPC

Dr. Jarrard

11:35 – 12:35 p.m. Case-based Roundtable Discussions

Case #1 –BCR and mHSPC – Dr. Boorjian

Case #2 - M0 CRPC - Dr. Cookson

 

Roundtable Discussants: All Faculty

12:35 – 1:35 p.m. Break

Session 2

1:35 – 1:55 p.m. Role of Immunotherapy and PARP Inhibitors

Dr. Morgans

1:55 – 2:15 p.m. Radionuclide Therapy and Bone Health

Dr. Boorjian

2:15 – 3:05 p.m. Case-based Roundtable Discussion: Chemotherapy-naive

Case #3: Early M1 CRPC Management (Docetaxel vs. Oral Agents vs. Immunotherapy) – Dr. Stratton

Case #4: Advanced M1 CRPC (Docetaxel and Ra-223) – Dr. Morgans

 

Roundtable Discussants: All Faculty

3:05 – 3:20 p.m. Break

Session 3

3:20 – 3:45 p.m. Role of Chemotherapy and Treatment Sequencing

Dr. Lang

3:45 – 4:45 p.m. Case-based Roundtable Discussion: Post-Chemotherapy

Case #5: Role of Genetic Testing in Advanced M1 CRPC (Immunotherapy or PARP Inhibitors) – Dr. Gomella

Case #6: M1 CRPC Post-docetaxel Chemotherapy and End-of-Life Care (Neuroendocrine) – Dr. Lang

David F. Jarrard, Lang

Welcome, Pre-Test, Session 1, Session 2, Session 3

Inglês

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES
 

Speakers

Michael S. Cookson, David F. Jarrard, Boorjian, Stratton, Gomella, Morgans, Lang

 
 
 
 

Download the Agenda

Search for our next event. See you soon!

Subscribe to get news on all upcoming events

who%20goals_edited.png

DocMeeetings

Social Media

  • Twitter DocMeetings
  • Instagram DocMeetings
  • Facebook ícone social
  • LinkedIn ícone social

contact us

Adress

Sao Paulo, SP - Brazil

© 2020 by Docmeetings - A DocMeetings.com Company
Site Managed by:
QUALITY Soluções Web
1996-2020 "24 years inspiring technology"